{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:42:52Z","timestamp":1793421772780,"version":"4.5.0"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:p>Data on survival of BRCA1\/2\u2010associated primary breast cancer (PBC) patients who opt for subsequent contralateral risk\u2010reducing mastectomy (CRRM) are scarce and inconsistent. We examined the efficacy of CRRM on overall survival in mutation carriers with a history of PBC. From a Dutch multicentre cohort, we selected 583 BRCA\u2010associated PBC patients, being diagnosed between 1980 and 2011. Over time, 242 patients (42%) underwent CRRM and 341 patients (58%) remained under surveillance. Survival analyses were performed using Cox models, with CRRM as a time\u2010dependent covariate. The median follow\u2010up after PBC diagnosis was 11.4 years. In the CRRM group, four patients developed contralateral breast cancer (2%), against 64 patients (19%) in the surveillance group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The mortality was lower in the CRRM group than in the surveillance group (9.6 and 21.6 per 1000 person\u2010years of observation, respectively; adjusted hazard ratio 0.49, 95% confidence interval 0.29\u20130.82). Survival benefit was especially seen in young PBC patients (&lt;40 years), in patients having a PBC with differentiation grade 1\/2 and\/or no triple\u2010negative phenotype, and in patients not treated with adjuvant chemotherapy. We conclude that CRRM is associated with improved overall survival in BRCA1\/2 mutation carriers with a history of PBC. Further research is warranted to develop a model based on age at diagnosis and tumour and treatment characteristics that can predict survival benefit for specific subgroups of patients, aiming at further personalized counselling and improved decision making.<\/jats:p>","DOI":"10.1002\/ijc.29032","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T11:45:14Z","timestamp":1403264714000},"page":"668-677","source":"Crossref","is-referenced-by-count":182,"title":["Improved overall survival after contralateral risk\u2010reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis"],"prefix":"10.1002","volume":"136","author":[{"given":"Bernadette A.M.","family":"Heemskerk\u2010Gerritsen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Family Cancer Clinic, Erasmus MC Cancer Institute Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti A.","family":"Rookus","sequence":"additional","affiliation":[{"name":"Department of Epidemiology NKI\u2010AVL Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora M.","family":"Aalfs","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics AMC Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet G.E.M.","family":"Ausems","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics UMCU Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.","family":"Coll\u00e9e","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics EMC Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Surgery UMCG Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Marleen","family":"Kets","sequence":"additional","affiliation":[{"name":"Department of Human Genetics Radboud University Nijmegen Medical Centre Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien B.M.I.","family":"Keymeulen","sequence":"additional","affiliation":[{"name":"Department of Surgery MUMC Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linetta B.","family":"Koppert","sequence":"additional","affiliation":[{"name":"Department of Surgery Erasmus MC Cancer Institute Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne E.J.","family":"Meijers\u2010Heijboer","sequence":"additional","affiliation":[{"name":"Department of Human Genetics VUMC Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea M.","family":"Mooij","sequence":"additional","affiliation":[{"name":"Department of Epidemiology NKI\u2010AVL Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob A.E.M.","family":"Tollenaar","sequence":"additional","affiliation":[{"name":"Department of Surgery LUMC Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans F.A.","family":"Vasen","sequence":"additional","affiliation":[{"name":"Foundation for Detection of Hereditary Tumours Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"HEBON","sequence":"additional","affiliation":[{"name":"Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Collaborating Centers: Coordinating center: Netherlands Cancer Institute, Amsterdam, NL: M.A. Rookus, F.B.L. Hogervorst, F.E. van Leeuwen, S. Verhoef, M.K. Schmidt, J.L. de Lange; Erasmus Medical Center, Rotterdam, NL: J.M. Coll\u00e9e, A.M.W. van den Ouweland, M.J. Hooning, C. Seynaeve, C.H.M. van Deurzen, I.M. Obdeijn; Leiden University Medical Center, NL: C.J. van Asperen, J.T. Wijnen, R.A.E.M. Tollenaar, P. Devilee, T.C.T.E.F...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Family Cancer Clinic, Erasmus MC Cancer Institute Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Seynaeve","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Family Cancer Clinic, Erasmus MC Cancer Institute Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91578-4"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07065-7"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3396"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0805-3"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt095"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00203-7"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000072105.39021.6d"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.01.007"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.3645"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9709-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(00)00505-5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3938"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602703"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.080"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24129"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-009-0528-5","article-title":"Contralateral risk\u2010reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high\u2010risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)","volume":"120","author":"Kiely B","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1136-7"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2299-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2583-1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq018"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g226"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0476-0"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.13.941"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780030106"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.124"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1359-6349(10)70521-8","article-title":"Is risk\u2010reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival?","volume":"8","author":"Heemskerk\u2010Gerritsen BAM","year":"2010","journal-title":"Eur J Cancer"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1479-1"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9430"},{"key":"e_1_2_7_30_1","first-page":"1","article-title":"Risk of second breast cancer according to estrogen receptor status and family history","author":"Bouchardy C","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0769-3"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0894-z"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020989"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.052"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2008.0067"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1237"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.29032","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.29032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:00:51Z","timestamp":1696370451000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.29032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,8]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1002\/ijc.29032"],"URL":"https:\/\/doi.org\/10.1002\/ijc.29032","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,8]]}}}